PMID- 37334299
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20230620
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Obesity is associated with impaired postprandial pancreatic polypeptide 
      secretion.
PG  - 1192311
LID - 10.3389/fendo.2023.1192311 [doi]
LID - 1192311
AB  - OBJECTIVE: This study aims to compare the levels of serum pancreatic polypeptide 
      (PP), insulin (INS), C-peptide (C-P), and glucagon (GCG) before and after glucose 
      stimulation in type 2 diabetes mellitus (T2DM) patients with different body mass 
      indexes (BMI), analyze the relevant factors associated with PP secretion, and 
      further investigate the role of PP in the development of obesity and diabetes. 
      METHODS: Data were collected from 83 patients from the hospital. The subjects 
      were divided into normal-weight group, overweight group, and obese group 
      according to their BMI. All subjects were tested with the standard bread meal 
      test (SBMT). PP and relevant parameters were measured, and the area under the 
      curve (AUC) was calculated after 120 min of SBMT. AUC(pp) (AUC of PP) was used as 
      the dependent variable, and the potential influencing factors were used as 
      independent variables for multiple linear regression analysis. RESULTS: The obese 
      and overweight groups had significantly lower PP secretion than the normal-weight 
      group (485.95 pg.h/ml, 95% CI 76.16-895.74, p = 0.021; 664.61 pg.h/ml, 95% CI 
      285.46-1043.77, p = 0.001) at 60 min postprandial. PP secretion in the obese and 
      overweight groups was also significantly lower than that in the normal-weight 
      group (520.07 pg.h/ml, 95% CI 186.58-853.56, p = 0.003; 467.62 pg.h/ml, 95% CI 
      159.06-776.18, p = 0.003) at 120 min postprandial. AUC(pp) was negatively 
      associated with BMI (r = -0.260, p = 0.017) and positively associated with 
      AUC(GCG) (r = 0.501, p< 0.001). Multiple linear regression analysis showed that 
      there was a linear correlation between AUC(GCG), BMI, and AUC(pp) (p< 0.001, p = 
      0.008). The regression equation was calculated as follows: AUC(pp) = 
      1772.255-39.65 x BMI + 0.957 x AUC(GCG) (R(2 = )54.1%, p< 0.001). CONCLUSION: 
      Compared with normal-weight subjects, overweight and obese subjects had impaired 
      PP secretion after glucose stimulation. In T2DM patients, PP secretion was mainly 
      affected by BMI and GCG. CLINICAL TRIAL REGISTRY: The Ethics Committee of the 
      Affiliated Hospital of Qingdao University. CLINICAL TRIAL REGISTRATION: 
      http://www.chictr.org.cn, identifier ChiCTR2100047486.
CI  - Copyright (c) 2023 Zhao, Zhou, Chi, Che, Wang and Wang.
FAU - Zhao, Yanyun
AU  - Zhao Y
AD  - Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao 
      University, Qingdao, China.
FAU - Zhou, Yue
AU  - Zhou Y
AD  - Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao 
      University, Qingdao, China.
FAU - Chi, Jingwei
AU  - Chi J
AD  - Medical Research Center, Qingdao Key Laboratory of Thyroid Diseases, Qingdao, 
      China.
FAU - Che, Kui
AU  - Che K
AD  - Medical Research Center, Qingdao Key Laboratory of Thyroid Diseases, Qingdao, 
      China.
FAU - Wang, Yangang
AU  - Wang Y
AD  - Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao 
      University, Qingdao, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Hematology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230602
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 59763-91-6 (Pancreatic Polypeptide)
RN  - 9007-92-5 (Glucagon)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Humans
MH  - *Overweight/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Pancreatic Polypeptide
MH  - Obesity/complications
MH  - Glucagon
MH  - Glucose
PMC - PMC10273268
OTO - NOTNLM
OT  - T2DM
OT  - glucagon
OT  - islet function
OT  - obesity
OT  - pancreatic polypeptide
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/19 06:41
MHDA- 2023/06/20 06:42
PMCR- 2023/01/01
CRDT- 2023/06/19 03:05
PHST- 2023/03/23 00:00 [received]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/06/20 06:42 [medline]
PHST- 2023/06/19 06:41 [pubmed]
PHST- 2023/06/19 03:05 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1192311 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jun 2;14:1192311. doi: 
      10.3389/fendo.2023.1192311. eCollection 2023.